Detecting Tumor Reactivity of Autologous and Allogeneic γδ T Cells via Tumor Organoid-Immune Cells Co-Culture

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: Cancer immunotherapies primarily target conventional αβ T cells, yet their clinical effectiveness is frequently undermined by immune evasion mechanisms inherent to tumors. γδ T cells, a distinct class of unconventional lymphocytes, recognize tumor-associated antigens independently of MHC molecules, potentially overcoming these limitations. However, comprehensive evaluations of γδ T cell functionality within the tumor microenvironment (TME) remain scarce. Methods: We developed an innovative patient-derived tumor organoid (PDTO) and immune cell co-culture platform, integrating autologous tumor-infiltrating lymphocytes (TILs) and healthy donor-derived allogeneic Vγ9Vδ2 T cells. Utilizing fluorescent cell-tracing, multiplex cytokine analyses, and flow cytometry, we assessed γδ T cell infiltration, activation, and cytotoxicity within breast cancer organoids, closely mimicking physiological tumor conditions. Results: Our findings reveal that autologous γδ T cells demonstrate significantly enhanced tumor-specific activation compared to conventional αβ T cell subsets, as indicated by elevated CD137 expression. Additionally, allogeneic Vγ9Vδ2 T cells exhibited robust cytotoxic activity against breast cancer organoids, with cytotoxic efficacy correlating with higher effector-to-target ratios and increased secretion of IFN-γ, granzyme B, and perforin. Conclusion: The established PDTO–immune cell co-culture platform provides a physiologically relevant model for evaluating γδ T cell reactivity and cytotoxicity. These results underscore the potential of γδ T cells as effective candidates for cancer immunotherapy, offering significant promise for developing novel therapeutic strategies against solid tumors.

Article activity feed